Hb AS

Hb AS

abbr.
hemoglobin A and hemoglobin S (heterozygous state) (the sickle cell trait)

Patient discussion about Hb AS

Q. Please precribe for me the possible medicine (treatment) for sickle cells. Secondly, my boy lost hearing at 4 1- I need to know how sickle cells can be treated. 2- My boy just surprisingly lost his abillity to hear anything at the age of 4.

A. wow...you are going through some hard times...it's the hardest thing in the world seeing your children in pain. loosing his hearing could be caused by clots that were formed and destroyed the ear nerve. but it's unlikely it happened in both ears...so i would check it out. and about treatment- there are a variety of treatments, so i found a web site with them all. and even some that are still in research: http://www.nhlbi.nih.gov/health/dci/Diseases/Sca/SCA_Treatments.html

More discussions about Hb AS
References in periodicals archive ?
In order to emphasize the use of Hb as the only parameter for anaemia assessment without losing the advantage of Hct measurements, the use of the three-fold conversion to equate the two measures has come into practice (6).
However, significant ranges of anaemia has been observed with Hb as low as 5.7 g/dL.
It was observed that intracellular generation of reactive oxygen species (ROS) was inhibited significantly in the cells expressing excess of Hb as determined by immunofluorescence studies.
An increase in the frequency of Hb monitoring during an acute event can help highlight a trend of increasing Hb as the underlying condition is resolved, thereby allowing a timely decrease in the Epoetin alfa dose to ensure that Hb levels do not exceed 12 g/dL.
Labile hemoglobin [A.sub.1c] (Hb [A.sub.1c]), or pre-Hb [A.sub.1c], is an intermediate in the synthesis of Hb [A.sub.1c] and is characterized by the reversible binding of glucose to Hb as a Schiff base (1).
Thus, ongoing or periodic use of Hct to assess anemia outcomes may lead to inconsistent and inaccurate results; the NKFK/DOQI[TM] guidelines recommend using Hb as the primary means of quantifying the level of anemia in patients with ESRD (National Kidney Foundation, 2001).
(n) Hb AS, Hb SS, Hb SC, Hb S/ [beta]-thal, Hb SE, Hb SG-Philadelphia, Hb SO-Arab, Hb SJ-Toronto, and Hb SFukuyama included.
Thus, ongoing or periodic use of Hct to assess anemia outcomes may lead to inconsistent and inaccurate results; the NKF K/DOQI[TM] guidelines recommend using Hb as the primary means of quantifying the level of anemia in patients with ESRD (NKF-K/DOQI, 200l).
For each test method, results for each group of samples (Hb AA, Hb AC, Hb AS) were compared with results from the comparative method (CLC 330).
For each test method, results for each group of samples (Hb AA, Hb AC, and Hb AS) were compared with results from the comparison method (CLC 330).
Recently, the effects of Hb AC and Hb AS on one gHb immunoassay method were assessed (5).
For example, the total glycoHb in a sickle cell trait carrier (Hb AS) is Hb [A.sub.1c], + Hb [S.sub.1c].